الفهرس 
Fatty Liver DiseaseOnly 14 pages are availabe for public view
 |  | from | 186 |  |  |
| | | from | 186 | | |
Abstract
Fatty liver, or hepatosteatosis, is characterized histologically by triglyceride accumulation within the cytoplasm of hepatocytes and refers to fat accumulation in the liver exceeding 5%–10% by weight. /Non alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disorders ranging from simple steatosis to inflammatory steatohepatitis (NASH) and cirrhosis. Of those who develop NASH, about 20% of patients will develop cirrhosis during their lifetime. Therefore, a diagnosis of NASH may result in a more aggressive therapeutic approach toward the metabolic risk factors. The combination of (TE) with one or more of the serum marker panels might be a potential approach for the non-invasive measurement of fibrosis in NAFLD. The combination of TE and FibroTest was found to have the best diagnostic performance, compared to either test alone. The aim of the present study is to determine the diagnostic utility of fibrotest, fibrosis 4 score, NAFLD fibrosis score and transient elastography as non-invasive biomarkers of fibrosis in patients with non alcoholic fatty liver disease. As regards laboratory investigations, patients with moderate to severe fibrosis have statistically higher significant differences than patients with mild fibrosis as regards serum alanine aminotransferase, aspartate aminotransferase and total bilirubin levels. The diagnostic accuracy of NAFLD fibrosis score at a cutoff value 0.46 in the detection of metavir stage f2 and higher was 94.7% with a sensitivity and specificity 89.4% and 90.2% respectively, while the diagnostic accuracy of FIB_4 score at a cutoff value 1.43 in the detection of metavir stage f2 and higher was 99.2% with a sensitivity and specificity 94.7% and 97.6% respectively.